Table 2 Genetically modified MSCs in organ failure and related conditions (preclinical studies)
Condition | Cell Source | Gene | Study type | Results (ref) |
|---|---|---|---|---|
Liver failure | UCB | VEGF65 | In vivo (rat) | Stimulation of substantial therapeutic influences on ALF [154] |
Heart failure | BM | ADM | In vivo (rat) | Enhanced heart function and decreased fibrotic area volume and MMPs levels in heart tissue [119] |
Heart failure | BM | HGF | In vivo (rat) | Improved LV systolic and diastolic function [197] |
Heart failure | BM | VEGF | In vivo (swine) | Enhanced neovascularization, reduced hypertrophy, potentiated myocardial bioenergetic characteristics, and contractile function [198] |
Renal failure | BM | IDO | In vivo (mice) | Regeneration of the renal tissue by adjusting the polarization of the macrophage [199] |
Lung failure | BM | HO-1 | In vitro | Improved pro-survival, anti-apoptotic, and paracrine functions of MSCs-HO-1 [103] |
In vivo (rat) | ||||
Liver failure | UC | HNF4α | In vivo (mice) | Eliciting the marked therapeutic influences on ALF [200] |
Heart failure | BM | ILK | In vivo (swine) | Ameliorating the ventricular remodeling and cardiac activity [201] |
Heart failure | BM | Gas6 | In vivo (rat) | Eliciting functional recovery [116] |
Liver failure | BM | CXCR4 | In vivo (mice) | Enhanced migration and ameliorated tissue damage by stimulating hepatoprotective influences [152] |
Heart failure | AT | Myocardin | In vitro | Enhanced myogenic marker expression, blood flow as well as arteriogenesis [202] |
BM | In vivo (mice) | |||
Heart failure | BM | VEGF | In vivo (rat) | Reduced cardiomyocyte cell apoptosis in vitro and marked reduction of LV remodeling [118] |
Renal failure | iPS | miR-19a miR-20a | In vitro | Improved renal function [132] |
In vivo (rat) | ||||
Renal failure | UC | IGF-1 | In vivo (rat) | Ameliorated biochemical variables in serum or urine related to renal function [203] |
Renal failure | BM | TGF-β1 | In vivo (rat) | Improved renal ischemic reperfusion injury (IRI) by targeting the CXCR4 expression on cell membranes [204] |
Liver failure | AF | IL-1R antagonist | In vivo (rat) | Enhanced liver function and prolonged survival [205] |
Ovarian failure | BM | miR-21 | In vivo (rat) | Restoring ovarian function by decreasing granulosa cell apoptosis [165] |